EA Pharma is the gastrointestinal specialty pharmaceutical company with a full value chain including research and development, production and logistics, sales and marketing. It was established in April 2016 after integration of Eisai's gastrointestinal disease business built up over more than 60 years and the pharmaceutical business focused on gastrointestinal disease area of the Ajinomoto Group with amino acids at its core. The integration of the product development and pipelines of Eisai Group and the Ajinomoto Group allows EA Pharma to provide a product line-up that comprehensively covers the upper and lower digestive tracts, liver and pancreas, and to offer a wide range of solutions and high level of expertise in the gastrointestinal area.
The targeted disease, NASH, is a medical condition with high unmet medical needs that has fatty liver as its underlying disease, and in some cases, it results in cirrhosis and hepatocellular carcinoma. Nevertheless, there has been no promising drug with both high efficacy and safety; therefore, development of a novel drug has been anticipated.
The client has thus issued this open request to achieve early launch of innovative NASH treatment drug by combining EA Pharma’s expertise and the new drug candidates to be proposed.
Anticipated Project Phases or Project Plan
Respondents should submit proposals using the attached Response Template.
The client will review submitted proposals and possibly ask clarifying questions before selecting the most suitable candidates for collaboration. The client will select the best candidate(s) through evaluations. During the selection process, the client may execute non-disclosure agreements (NDA) with selected respondent(s), seek further information disclosure, and discuss specific development targets or potential opportunities. The client will execute necessary agreement(s) with the selected respondent(s) and move to the advanced development phase. Specifics of any collaboration will be determined through consultation with the concerned parties.